Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Phase III Setback For Merck's Antithrombotic Damages One Of The Key Assets Of The Schering Merger

This article was originally published in The Pink Sheet Daily

Executive Summary

Merck does not yet know why DSMB decided no longer to study vorapaxar in stroke and ACS patients, but market analysts suspect a finding of excess bleeding.
Advertisement

Related Content

Merck’s CV Pipeline: A Shrinking But Strident Commitment
Bleeding Rates In TRA-2P Further Dim Outlook For Merck’s Vorapaxar
Bleeding Rates In TRA-2P Further Dim Outlook For Merck’s Vorapaxar
Despite Recent Setbacks, Merck's CV Pipeline Is Strong
Despite Recent Setbacks, Merck's CV Pipeline Is Strong
Merck Pulls EPS Guidance To Avoid "Indiscriminate Short-Term Cost Cutting"
Vorapaxar Woes Increase Pressure On Remainder Of Merck CV Pipeline
Intracranial Hemorrhage The Culprit In Merck's Vorapaxar Trial
Merck R&D: A Jam-Packed Pipeline But Much Of It Wait-And-See
Merck R&D: A Jam-Packed Pipeline But Much Of It Wait-And-See

Topics

Advertisement
UsernamePublicRestriction

Register

PS071692

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel